Multcenter phase 1 study of the antibody drug conjugate MRG003 for advanced solid tumors
Prof. Rui-Hua Xu
The antibody drug conjugate MRG003 comprises and anti-EGFR monoclonal antibody that is conjugated with MMAE via a valine-citrulline linker. A multicenter phase 1 study in China found that MRG003 had a manageable safety profile and promising activity
for advanced EGFR-positive nasopharyngeal carcinoma and squamous cell carcinomas of the head and neck, with confirmed objective response rates of 44% and 40%, respectively.
